Adebrelimab or placebo plus carboplatin and etoposide as first …
2022年5月13日 · In the phase 3 CAPSTONE-1 trial, the combination of adebrelimab, a novel and potent humanised IgG4 anti-PD-L1 monoclonal antibody, and carboplatin and etoposide led to a significant improvement in overall survival by 2·5 months compared with placebo plus chemotherapy in untreated patients with ES-SCLC.
75P Real-world data of adebrelimab in the first-line treatment of ...
Adebrelimab is a novel humanised IgG4 monoclonal antibody against PD-L1, indicated for the first-line treatment of adult Patients with ES-SCLC in China. A registry study was conducted with the use of disease-specific database of lung cancer, at 21 Centres in Jiangsu, China.
84P Adebrelimab plus chemotherapy (chemo) as first-line …
In the phase 3 CAPSTONE-1 study, adebrelimab, a humanized IgG4 anti-PD-L1 monoclonal antibody, plus chemo as first-line treatment for ES-SCLC significantly improved overall survival (OS) vs placebo plus chemo. Here we reported updated outcomes ∼3 years after the enrollment of the last patient.
Neoadjuvant adebrelimab in locally advanced resectable …
2023年7月24日 · Adebrelimab is a high-affinity, humanized monoclonal antibody against PD-L1, which has been demonstrated to be effective and safe in advanced ESCC 16, extensive-stage small-cell...
Adebrelimab or placebo plus carboplatin and etoposide as first …
Immunotherapy has shown robust clinical activity in ES-SCLC in previous phase 3 trials. We aimed to assess the efficacy and safety of adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, with standard chemotherapy as a first-line treatment for ES-SCLC.
Adebrelimab plus chemotherapy and sequential thoracic …
This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small–cell lung cancer (ES-SCLC).
744P Safety, tolerability, pharmacokinetics, pharmacodynamics …
Adebrelimab (SHR-1316) is a novel humanized IgG4 monoclonal antibody showing high affinity for PD-L1 in preclinical studies. This open-label, first-in-human trial aimed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical efficacy in patients with advanced solid tumors who had failed standard ...
Definition of adebrelimab - NCI Drug Dictionary - NCI
adebrelimab An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities.
Adebrelimab (SHR-1316) in Combination With Chemotherapy as ...
2022年7月21日 · This study evaluated adebrelimab (a programmed death-ligand 1 antibody) plus nab-paclitaxel and carboplatin as perioperative treatment for resectable NSCLC.
Overall survival of adebrelimab plus chemotherapy and sequential ...
2024年5月29日 · Background: The phase 3 trial (CAPSTONE-1) showed that adebrelimab (PD-L1 antibody) combined with first-line chemotherapy could prolong overall survival (OS) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).
- 某些结果已被删除